IL33 and Alzheimer disease: In an animal study using AD mouse models, peripheral IL-33 administration was shown to decrease the levels of soluble Aβ and the deposition of amyloid plaque and reverse the deterioration in synaptic plasticity and cognitive functions (Fu et al. 2016).